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1. Introduction
Hepatic tumors in children are relatively rare, accounting for 1 to 4% of all pediatric solid tu‐
mors. [1] Primary liver masses constitute the third most common group of solid abdominal tu‐
mors of childhood [2] with an incidence of 0.4 to 1.9 per million children each year. [3,4]
Liver masses in children can be malignant, benign, or indeterminate and they are a diverse
group of epithelial and mesenchymal tumors whose incidence can vary considerably with
patient age. [5] Two thirds of liver tumors in children are malignant. [6] Unlike liver tumors
in adults, in which the predominant histology is hepatocellular carcinoma, hepatoblastoma
accounts for two thirds of liver tumors in children. [7] Other liver malignancies in children
include sarcomas, germ cell tumors, and rhabdoid tumors, as well as the more familiar hep‐
atocellular carcinoma. Benign tumors of the liver in children include vascular tumors, ha‐
martomas, adenomas, and focal nodular hyperplasia. The histology and anatomy of a
pediatric liver tumor guides the treatment and prognosis. [8]
In this chapter we outline the epidemiology, etiology, pathology, clinical presentation, diag‐
nosis and management of each of the most important types of liver tumor. Also aspects of
the surgical anatomy and resection techniques and other ways to improve ressecability in
liver tumors in childhood will be described such as portal vein thrombosis, chemotherapy
and transarterial chemoembolization (TACE).
2. Epidemiology
The incidence of hepatic tumors in childhood is consistently quoted from many series as be‐
ing in the region of 0.5-2.5 per million population [9] and approximately 100–150 new cases
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of liver tumors are diagnosed in the U.S. annually. [7] Two thirds of liver tumors in children
are malignant. [6] acounting for slightly more than 1% of all pediatric malignancies and
among those there is a male preponderance of 1.8 : 1. [7,10]
Hepatoblastoma presents in a younger age group, being a uncommon diagnosis over the
age of 4 years. Hepatocellular carcinoma has its peak onset in early adolescence, although
the range is wide. The older age at onset for hepatocarcinoma may well reflect its close asso‐
ciation with other underlying disease processes. [10]
There are several suggestions that the incidence of malignant liver tumors is increasing in
the U.S. Surveillance, Epidemiology, and End Results data from 1972–1992 showed a 5% an‐
nual increase. [7] Liver cancer represented 2% of all malignancies in infants in the early
1980s with the incidence doubling to 4% 10 years later. [11]
At a population level, there has been a dramatic increase in survival in countries in which a
modern health system has been implemented, although the increased survival is lower for
hepatocarcinoma in comparison with hepatoblastomas. [10] According to Litten & Tomlin‐
son [8], it has been suggested that the improvements in technology, care, and outcomes for
premature infants have been driving forces in the increase of the incidence in hepatic tu‐
mors. Hepatoblastoma is more commonly diagnosed in children with a history of prematur‐
ity than in full-term infants. Interestingly, those tumors that arise in ex-premature infants do
not present at a younger age than those of term infants. [8]
3. Hepatoblastoma
Hepatoblastoma is the most common malignant tumor of the liver in children and is an em‐
bryonal tumor in the classic sense of incomplete differentiation; [12] accounts for 1% of all
pediatric malignancies and for 79% of all liver cancers in children under age. [13] Its overall
incidence is 0.5–1.5 per million, however the incidence in children under the age of 18
months is 11.2 cases per million. [14]
Hepatoblastoma is diagnosed in very young children with a peak in the newborn period re‐
flecting those tumors that developed prenatally, and an overall median age at diagnosis of
18 months; 90 percent of cases are manifest by the fourth birthday, several have been
present at birth, and there is an hypothesized association with prematurity. [15] Only 5% of
new hepatoblastoma cases are diagnosed in children >4 years of age. [8]
The increased incidence of HB in children born before 28 weeks gestation (with birth weight
<1500 g) compared with term gestations, may be explained by the exposure of rapidly divid‐
ing hepatoblasts to endogenous metabolites and hormones as well as exogenous chemicals
that would normally be eliminated via the placenta. Inefficiency and compromise of the im‐
mature detoxification mechanisms could produce multiple somatic mutations and epigenet‐
ic (ie, methylation) modifications of the genome. [16, 17]
For poorly understood reasons, hepatoblastoma occurs in males significantly more frequent‐
ly than it does in females with a male:female ratio that ranges from 1.2 to 3.6:1. [14] Most
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commonly, these tumors present in the right lobe of the liver. [18] There is an increased inci‐
dence of hepatoblastoma in Beckwith-Wiedemann Syndrome, which has a relative risk of
2280 suggesting a role for genetic aberrations of chromosome 11 in the pathogenesis of hep‐
atoblastoma,[19, 20] hemihypertrophy, and familial adenomatous polyposis (FAP) witch has
a relative risk of 1220 suggesting a role for aberrations of chromosome 5 in the pathogenesis.
[21] Screening for cases in FAP kindred families is recommended by testing for germline
mutations in the APC tumor suppressor gene. [22, 23] Inactivation of the APC tumor-sup‐
pressor gene (found on chromosome 5) is found in 67–89% of sporadic hepatoblastoma [24,
25] This gene is known to regulate B-catenin and modulate the wnt signaling pathway, sug-
gesting a role for this signaling pathway in the development of hepatoblastoma. [26] Addi‐
tional biologic markers may include Trisomy 2, 8, and 20 and translocation of the NOTCH2
gene on chromosome 1. [27]
Many etiological factors have been linked with the development of malignant hepatic tu‐
mors in childhood (Table 1). Broadly speaking, genetic influences are particularly important
in the development of hepatoblastoma, whereas environmental factors and coexisting liver
disease are strongly associated with hepatocellular carcinoma. [10]
Hepatoblastoma Hepatocellular carcinoma
Beckwith-Wiedemann Syndrome Hepatitis B
Hemihypertrophy Hepatitis C
Familial adenomatous polyposis (FAP) Hereditary tyrosinemia
α1-Antitrypsin deficiency
Gardner syndrome Cirrhosis secondary to biliary atresia
Glycogen storage disease type I Glycogen storage disease type I
Trisomy 18 Neurofibromatosis
Fetal alcohol syndrome
Prematurity and low birth weight Familial adenomatous polyposis
Maternal exposure to: Drug/toxin exposure:
Oral contraceptives Androgens
Gonadotropins Oral contraceptives
Metals Methotrexate
Petroleum products Aflatoxins
Paints and pigments
Paternal exposure to: Fanconi anemia
Metals
Meckel diverticulum
Table 1. Conditions associated with hepatoblastoma and hepatocellular carcinoma.
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Hepatoblastomas are composed of cells resembling the developing fetal and embryonic liv‐
er, hence the classification as an embryonal tumor. Indeed, the cells comprising hepatoblas‐
toma mark similarly to hepatic stem cells, defined as pluripotent hepatoblasts capable of
differentiating into hepatocytes or cholangiocytes. [28, 29]
According to the Childhood Epithelial Liver Tumors – International Criteria (CELTIC) group,
the pathology of hepatoblastoma is classified into four groups based on the work of Weinberg
and Finegold: fetal, embryonal, macrotrabecular and small-cell undifferentiated. [10]
Histologically,  these  tumors  can  be  divided  into  epithelial  (56%)  or  mixed  epithelial/
mesenchymal tissue.  The epithelial  group is  further  subdivided into fetal  (31%),  embry‐
onal  (19%),  macrotrabecular  (3%)  and small-cell  undifferentiated subtypes  (3%).  Thema‐
jority  of  hepatoblastomas  is  epithelial  and  consist  of  a  mixture  of  embryonal  and  fetal
cell types (Fig. 1). [8, 30]
Figure 1. Distribution of histologic subtypes of hepatoblastoma. The majority are epithelial and consist of embryonal
and fetal cell types. Pure fetal histology accounts for approximately 7% of hepatoblastomas and is associated with a
favorable prognosis. Small cell undifferentiated hepatoblastoma accounts for 5% of hepatoblastoma cases and is as‐
sociated with a poor prognosis. [8]
Of the five histologic subtypes—pure fetal, embryonal, mixed epithelial, mesenchymal/
macrotrabecular, and small cell undifferentiated—fetal carries the most favorable prognosis.
[31] Approximately 5% of hepatoblastomas are of the small cell undifferentiated subtype.
This subtype is associated with a worse prognosis. [32] In the mixed epithelial/ mesenchy‐
mal type, the presence of mesenchymal elements is associated with improved prognosis and
the most common mesenchymal elements are cartilage and osteoid. [33]
Hepatoblastomas usually presents as a palpable asymptomatic mass with abdominal disten‐
sion. [10] Less common presentations include weight loss, anorexia, emesis and abdominal
pain and usually indicate advanced disease. [34] One of the more unusual presenting features
of hepatoblastoma is its association with sexual precocity due to the release of human chorion‐
ic gonadotropic hormone (β-HCG) by the tumor. Osteoporosis is said to occur in up to 20% of
the cases and when severe can lead to bone fractures and vertebral compression. [35] The tu‐
mor may rupture spontaneously, producing an acute abdomen and hemoperitoneum. [10]
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Approximately 90% of patients demonstrate elevated serum AFP levels and there is a corre‐
lation between AFP levels and extent of disease. [36]
The right lobe of the liver is most commonly involved with disease but in 35% of patients
there is bilateral disease. [37] Distant metastasis are present in 20% of patients at the time of
diagnosis with the lung being the most common site of metastasis; other common sites are
the brain and bone and metastasis occur more commonly with disease relapse. [38]
Hepatoblastoma (%) Hepatocellular carcinoma (%)
Abdominal mass 71 58
Weight loss 24 21
Anorexia 22 22
Pain 18 16
Vomiting 13 10
Jaundice 7 10
Table 2. Signs and symptoms of liver tumors in children. [10]
Overall, the diagnosis is based on laboratory tests (such as full blood count, liver function
tests, α-Fetoprotein – AFP and other markers), imaging (abdominal radiography, ultraso‐
nography, computer tomography, magnetic resonance imaging, hepatic angiography, chest
radiography and positron-emission tomography – PET) and biopsy.
The full blood count can reveal anemia (usually normocytic, normochromic) in at least 50% of
children with hepatoblastoma. [13, 39] The platelet count is also often abnormal with up to one-
third of patients demonstrating thrombocytosis and fewer patients having thrombocytopenia.
Thrombocytosis is thought to be related to increased levels of circulating thrombopoietin. [40]
Liver function tests are commonly normal in hepatoblastoma. [10] The serum alpha-fetopro‐
tein (AFP) level is elevated in 90% of children with hepatoblastoma and tumors that fail to
express AFP at diagnosis are felt to be biologically more aggressive. [41, 42] AFP levels must
be interpreted with caution because AFP is commonly elevated in normal neonates up to 6
months of age and may be slightly elevated in other tumors, as well as after hepatic damage
or during regeneration of liver parenchyma.
The imaging study is important in evaluation liver neoplasms. CT, MRI and ultrasound are
the most commonly used modalities for pediatric doctors in their medical researches as well
as their clinical practice. Ultrasound is accepted as a first-line imaging method because of its
less irradiation, greater convenience and better real-time. [43] Ultrasound is extremely val‐
uable in detecting much smaller lesions, especially in detecting fluid and blood-flow in a le‐
sion, and it also can evaluate the hepatic vascular anatomy.[44] As a rule, the initial
diagnosis of live tumor is usually made by the abdominal ultrasound examination, which
will identify the liver as the organ of origin. Hepatoblastoma are seen as a hyperechoic, sol‐
id, intrahepatic mass on US. [45]
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Both CT and MRI define the extent of tumor involvement showing its segmental extension
and its proximity to the portal vein, to help determine the resectability. Evaluation with CT
demonstrates a delineated hypoattentuated mass compared with the surrounding normal
tissue and allows identification of calcifications. [46] The use of contrast allows assessment
of vascular involvement by the tumor. Combined MRI and contrast enhanced MR-angiogra‐
phy gives the best evaluation of the vascular structures and the tumor blood supply, and
this best enables the planning of a resection. A diagnostic biopsy is recommended in all chil‐
dren with a suspected hepatoblastoma. Given the potential side effects of chemotherapy, it
is not a good clinical practice to start therapy in a patient in the absence of a tissue diagnosis.
Additionally, it is necessary to rule out HCC. Although it is rare, HCC have been reported in
children under the age of three and they carry a worse prognosis. [47]
Figure 2. CT scan of an infant with a large central hepatoblastoma.
Large multinodular expansile masses, hepatoblastomas radiographically appear well de‐
marcated from the normal liver but are not encapsulated. They may invade hepatic veins,
disseminate to the lungs, or penetrate the liver capsule to reach contiguous tissues. [12]
Historically, North Americans have staged liver tumors similar to other solid tumors, stag‐
ing system continues to be used by the children’s oncology group (COG) and depends upon
extent of surgery at the time of initial diagnosis.
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Relative number of patients presenting in each stage in the COG trial 9645 (1999–2003) is as
follows: Stage I (22%) indicates complete resection at diagnosis, Stage II (0.5%) microscopic
residual after attempted complete resection at diagnosis, Stage III (53%) biopsy at diagnosis
with gross residual tumor, and Stage IV (23%) metastatic disease at diagnosis.[48, 49] The
traditional COG staging system has been criticized for being rather subjective, depending to
a large extent on the surgeon rather than the tumor.[12, 50] To address this concern specific
surgical guidelines have been proposed by the COG liver tumor committee which define the
anatomic and biologic characteristics of a tumor for which resection at diagnosis is recom‐
mended. In addition the upcoming COG hepatoblastoma (AHEP 0731) protocol will add a
risk-based stratification of treatment as follows: low risk (Stage I/II lacking any unfavorable
biologic feature); intermediate risk (Stage III or Stage I/II with small cell undifferentiated his‐
tology); and high risk (Stage IV or Stage I/II/III with AFP <100 at diagnosis). [12]
3.1. Stage Information
There  are  two  standard  surgical  staging  systems  for  pediatric  liver  tumors.  The  Child‐
hood  Liver  Tumour  Strategy  Group  (SIOPEL)  uses  a  presurgical-based  staging  system,
while  the  Children's  Oncology  Group  (COG)  uses  a  postsurgical-based  staging  system.
The staging systems support different treatment strategies. The presurgical staging system
is used with neoadjuvant chemotherapy followed by definitive surgery (with the excep‐
tion of Pretreatment Extent of Disease [PRETEXT] stage 1), while the postsurgical staging
system has surgery as the initial strategy.
Both systems are used in the United States. In a retrospective comparison of the two stag‐
ing systems at diagnosis using data from patients entered on a North American random‐
ized  trial,  both  staging  systems  predicted  outcome.  The  presurgical  PRETEXT  staging
system may add prognostic information for patients staged postsurgically at stage 3. [51]
The COG is investigating the use of PRETEXT stage before and after chemotherapy to de‐
termine the optimal surgical approach. [52]
3.2. Presurgical Staging for Hepatoblastoma and Hepatocellular Carcinoma
The PRETEXT staging system for hepatoblastoma categorizes the primary tumor based on
extent of liver involvement at diagnosis. The staging system was devised for use in an inter‐
national hepatoblastoma treatment program in which only children with PRETEXT stage 1
hepatoblastoma undergo initial resection of tumor. All others are treated with chemothera‐
py prior to attempted resection of the primary tumor. The liver tumors are staged by inter‐
pretation of computerized tomography or ultrasound with or without additional imaging
by magnetic resonance. The presence or absence of metastases is noted in addition to the
PRETEXT stage, but does not alter the PRETEXT stage. Tumor involvement of the vena
cava, hepatic veins, and portal vein, and extrahepatic extension are also noted.
The imaged liver is divided into four quadrants and involvement of each quadrant with tumor
is determined. Stage increases and prognosis decreases as the number of quadrants radiologi‐
cally involved with tumor increases from one to four. [53, 50] Experienced radiologist review is
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important because it may be difficult to discriminate between real invasion beyond the ana‐
tomic border of a given sector and displacement of the anatomic border. [50, 43]
Figure 3. Pretext stage 1 - Tumor involves only one quadrant; three adjoining liver quadrants are free of tumor.
[http://www.cancer.gov/PublishedContent/MediaLinks/308970.html]
Figure 4. Pretext stage 2 - Tumor involves one or two quadrants; two adjoining quadrants are free of tumor. [http://
www.cancer.gov/PublishedContent/MediaLinks/308970.html]
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Figure 5. Pretext stage 3 - Tumor involves three quadrants and one quadrant is free of tumor or tumor involves two
quadrants and two nonadjoining quadrants are free of tumor. [http://www.cancer.gov/PublishedContent/Medi‐
aLinks/308970.html]
Figure 6. Pretext stage 4 - Tumor involves all four quadrants; there is no quadrant free of tumor. [http://
www.cancer.gov/PublishedContent/MediaLinks/308970.html]
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3.3. Treatment - Chemotherapy
During the past 30 years, there has been an improved survival for patients with HB based
on refinements in surgical techniques, a better understanding of the hepatic segmental anat‐
omy, advances in chemotherapy, and the advent of liver transplantation as a therapeutic
modality for patients with unresectable disease. HB is a surgical neoplasm and only com‐
plete tumor resection results in a realistic hope for cure. Long-term disappearance of tumor
with complete remission with chemotherapy alone has been anecdotally observed. Howev‐
er, chemotherapy is a cornerstone in the management of HB. [55]
Although chemosensitivity varies between patients, it is an essential component of the man‐
agement and complementary to radical surgical resection to affect a cure. In general, surgeons
agree that preoperative chemotherapy helps to reduce the size of most tumors and obtains bet‐
ter demarcation between the tumor and surrounding liver tissue. [56, 57, 58] Consequently, tu‐
mors are more likely to be completely resected without increasing perioperative morbidity or
mortality. It is also speculated that residual microscopic disease may behave more aggressive‐
ly under the influence of hepatotrophic factors stimulating liver regeneration if preoperative
chemotherapy has not been used. [58] On the other hand, von Schweinitz et al. [59] have shown
that there is little to be gained from prolonging chemotherapy beyond the planned treatment
regimen, which incurs the risk of developing chemoresistance. [55]
Even if unresectable at diagnosis, most hepatoblastomas are unifocal and chemosensitive,
especially to ‘‘platinum’’ derivative chemotherapeutic agents. With the routine addition of
cisplatin to the chemotherapy in the late 1980s, overall survival in hepatoblastoma increased
from 30% to 70%. [60, 61] Twenty years later, cisplatin remains the backbone of the chemo‐
therapy regimen. In current trials by COG (America), SIOPEL (Europe, South America),
GPOH (German), and JPLT (Japan) chemotherapeutic agents used in combination with cis‐
platin have differed slightly. Although most use some form of doxorubicin, COG currently
recommends Cisplatin/5FU/Vincristin (C5V) for low-risk tumors, C5V+Doxorubicin for in‐
termediate risk, and hopes to investigate new agents with up-front window therapy in high-
risk tumors. [48, 49] Irinotectan, with or without doxorubicin, has been used in both
America and Europe for patients with relapse. [62] Because tumor cells may become resist‐
ant to chemotherapy over prolonged exposure [63] and because cumulative chemotherapy
toxicity may be unwarranted, prolonged (44 cycles) courses of neoadjuvant chemotherapy
are discouraged by all study groups. Early referral for complex surgical planning may be in‐
dicated for large invasive tumors potentially requiring transplantation. [12]
Two principle strategies exist. In the United States, tumor resection at diagnosis, whenever
prudently possible, has been advocated with the argument that toxicity of chemotherapy
can be reduced by avoidance of unnecessary neoadjuvant chemotherapy, that some tumors
may become resistant to prolonged courses of chemotherapy [64] and the highest survival
rates have historically been observed in patients with initially resected tumors—although
these tumors also tend to be the smaller more favorable tumors. Proposed COG Surgical
guidelines advocate definitive surgical resection at diagnosis for localized, unifocal PRE‐
TEXT I and II tumors followed by chemotherapy. When the tumor is large (PRETEXT III or
IV), multicentric, shows radiographic evidence of portal or hepatic venous invasion, or pul‐
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monary metastatic lesions the chance of curative resection may be improved neoadjuvant
chemotherapy and delayed primary resection. Alternatively, the SIOPEL study group dis‐
courages resection of hepatoblastoma at diagnosis favoring neoadjuvant chemotherapy in
all patients with the argument that the chemotherapy renders most tumors smaller, better
demarcated, and more likely to be completely resected, and that the toxicity of neoadjuvant
chemotherapy is offset by the increased rates of surgical resectability. Both COG and SIO‐
PEL have invested considerable effort in attempts to decrease the significant ototoxiciy at‐
tendant to the use of cisplatin based chemotherapy in young infants and toddlers. [12]
In the Intergroup Hepatoblastoma/ Hepatocellular Carcinoma Study, 28% of HB tumors were
completely resected at diagnosis (Stage I) and 4% (Stage II) were incompletely excised. These
patients had a 91% and 100% 5-year survival, respectively. However, the surgical guidelines of
the protocol lacked clear recommendations regarding which tumor should or should not be re‐
sected at diagnosis. The study compared the use of cisplatin and doxorubicin in one treatment
arm to cisplatin, vincristine, and 5-fluorouracil (5-FU) in the other arm. The overall 3- year sur‐
vival rates were 63% and 71%, respectively. [65] Although the difference between the groups
was not significant, the cisplatin/ doxorubicin group had a higher toxicity rate. A significant re‐
sponse to preoperative chemotherapy was observed in Stage III patients allowing complete tu‐
mor resection in 70–80% of these cases. Pre-operative chemotherapy had no effect on operative
mortality; however, increased transfusion requirement and a higher operative morbidity was
observed in patients that received chemotherapy preoperatively. [55]
The studies coordinated by the SIOPEL group have concentrated on using preoperative che‐
motherapy. [56, 66] In SIOPEL-1, all patients were treated preoperatively with four courses
of cisplatin and doxorubicin (PLADO); surgical resection was followed by two more courses
of chemotherapy. If the tumor was judged unresectable by imaging after four courses of che‐
motherapy, attempting surgical resection was delayed until after the sixth course. If the tu‐
mor remained localized to the liver but was still unresectable, liver transplantation was
recommended as the primary operative procedure if some response to chemotherapy had
been obtained in the absence of extrahepatic tumor extent or metastatic disease. The SIO‐
PEL-2 pilot study [67]was designed to test the efficacy and toxicity of two chemotherapy
regimens, one for patients with HB confined to the liver and involving no more then three
hepatic sections ‘‘standard-risk (SR) HB”, and one for instances of HB extending into all four
sections and/or with lung metastases or intra-abdominal extrahepatic spread or tumor rup‐
ture at presentation or with serum AFP < 100 units at presentation ‘‘high-risk (HR) HB”.
Those with SR-HB were treated with four courses of cisplatin monotherapy, delayed sur‐
gery, and then two more courses of cisplatin. Patients with HR-HB were given cisplatin al‐
ternating with carboplatin and doxorubicin, pre- and postoperatively. For SR-HB patients (n
= 77), and HR-HB patients (n = 58), the 3-year progression-free survival rates were 89% and
48%, respectively. For SR-HB patients, the efficacy of cisplatin monotherapy and the cispla‐
tin/doxorubicin combination are now being compared in a prospective randomized trial
(SIOPEL-3 study). For HR-HB patients, intensified chemotherapy with cisplatin, doxorubi‐
cin, and carboplatin is being investigated in a SIOPEL-4 study. [55]
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In unifocal HB, PRETEXT grouping based on imaging studies at diagnosis in some cases
may lead to overstaging the tumor from PRETEXT III to PRETEXT IV when the anatomic
border separating a lateral section from the sections of the liver harboring the bulging mass
is simply displaced (due to compression) but not invaded. [56, 68] Indeed, repeat imaging
studies after chemotherapy, when the tumor has shrunken, can demonstrate that the ana‐
tomic border is free from invasion and allow for correct staging and performance of a partial
hepatectomy (right or left trisegmentectomy). In multifocal HB with lesions scattered in the
different sections of the liver, clearance of one section, (e.g. the left lateral section) [69] can
apparently be achieved by chemotherapy in some cases, tempting the surgeon to perform a
partial rather than a total hepatectomy. However, this strategy is not recommended because
of the high-risk of leaving viable malignant tumor cells in the remaining section. Therefore,
in multifocal hepatoblastoma, liver transplantation is the best treatment option, whatever
the apparent result of chemotherapy. Further intensification of chemotherapy when the re‐
sponse to completion of full courses of chemotherapy according to protocol is considered
unsatisfactory, and hazardous attempts at partial liver resection in order to avoid liver trans‐
plantation ‘‘at any cost” are no longer justified since the efficacy of primary liver transplan‐
tation for unresectable HB has been validated during the last decade. [55]
Even patients presenting with metastatic disease are potentially curable with a combination of
chemotherapy, complete tumor resection by partial hepatectomy or transplantation, and pul‐
monary metastasectomy. The role of pulmonary metastasectomy has yet to be clearly defined,
although it appears that surgical resection of lung deposits may be more likely to cure patients
with disease present at diagnosis but persistent after neoadjuvant therapy rather than patients
with pulmonary relapse. [12] Data from the most recent COG study, 9645, show 3-year event-
free survival of 90% for Stage I–II, 50% for Stage III, and only 20% for Stage IV (Malogolowkin
et al., 2007). In the European SIOPEL II 3-year survival for standard risk tumors was 90% and
for high-risk tumors was 50%. Cure from hepatoblastoma mandates a complete gross resection
of the primary tumor at some point during the treatment regimen. [12]
3.4. Surgical resection
The objective of the surgical procedure is to obtain a complete resection of the tumor, both
macro- and microscopically, which is paramount for cure of HB (and other liver cancers).
The surgical strategy should be based on a sound knowledge of segmental liver anatomy as
described by Couinaud, [70] vascular occlusion techniques and expertise in performing the
different types of liver resections, including the most extensive procedures (left or right tri‐
segmentectomies). Intraoperative ultrasound is useful in confirming the location of major
vessels and other structures. Nonanatomical, atypical resections are best avoided, except in
rare cases (i.e., pedunculated tumor), because of an increased risk of incomplete tumor re‐
moval and a higher incidence of postoperative complications. [58] Very extensive liver re‐
sections (up to 80% of the liver mass) can be tolerated by young children with HB and
hepatic regeneration can be complete within 3 months, despite the administration of toxic
agents since they usually have no underlying liver disease and excellent hepatic reserve. [71]
Liver function rapidly returns to normal without long-term sequelae. Complete tumor resec‐
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tion can be easily achieved with a partial hepatectomy when the intrahepatic extent is limit‐
ed to one or two sections (PRETEXT I and II). When the tumor involves three sections
(PRETEXT III), preoperative neoadjuvant chemotherapy can make lesions initially consid‐
ered ‘‘unresectable” become resectable with a trisegmentectomy. [55]
Figure 7. Couinaud’s liver segmentation.
In centrally located HB, resection of Couinaud’s segments 4, 5 and 8 (‘‘central hepatecto‐
my”) can occasionally be performed by expert hands. When an accessory right hepatic vein
of appropriate size is present to drain remaining segments 5–7, subtotal hepatectomy re‐
moving segments 1–4 and 8 can be successfully performed. [55]
3.5. Liver transplantation
A growing experience with liver transplantation has shown that liver transplant is a good
treatment option in children with unresectable primary tumors and without demonstrable
metastatic disease after neoadjuvant chemotherapy and pulmonary metastasectomy if nec‐
essary. In large solitary, and especially multifocal, hepatoblastomas invading all four sec‐
tors of the liver,  transplantation has resulted in long-term disease free survival in up to
80% of children. [73] While most agree that ‘‘extreme’’ resection of tumors without liver
transplant will  avoid the need for long-term immunosuppressive therapy, hazardous at‐
tempts at partial hepatectomy in children with major venous involvement or with exten‐
sive  multifocal  tumors  should  be  discouraged.  [56,  69,  74,  75,  76]  Extensive  hepatic
surgery in  children should be  carried out  in  centers  that  have a  facility  for  liver  trans‐
plant, where surgical expertise, as well as willingness to embark on more radical surgery
with a transplant ‘‘safety net’’ is likely to be greater. [76]
Previous studies have validated the concept of total hepatectomy and primary orthotopic
liver transplantation (OLT) for unresectable HB. In SIOPEL-1, [77] 12 patients (8% of all pa‐
tients enrolled from 1990 to 1994) underwent liver transplantation as the primary surgical
option (after appropriate preoperative chemotherapy) in seven children, and as a rescue
procedure in five children because of incomplete partial resection or tumor relapse after par‐
tial hepatectomy. The long-term, disease-free patient survival was 66% for the entire series
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and 85% and 40% for primary transplants and rescue transplants, respectively. Current fol‐
low up is >10 years for all patients. All eight patients with PRETEXT IV tumors and all six
patients with multifocal HB were cured of their disease. Of the seven patients with macro‐
scopic extension into the portal vein and/or the hepatic veins/vena cava, 71% became long-
term, disease-free survivors, as well as four of five (80%) children who had lung metastases
at presentation with complete clearance of lung lesions after chemotherapy. [55]
An extensive review of the world experience collected 147 cases of liver transplantation for
HB. [77] Data were contributed by 24 centers (12 in North America, 10 in Europe, 1 in Japan
and Australia each). Twenty-eight (19% of the total) patients presented with macroscopic ve‐
nous extension and 12 (8%) with lung metastases. A total of 106 patients (72%) underwent a
primary transplant and 41 (28%) received a rescue transplant, either for incomplete resection
with partial hepatectomy or for tumor relapse after previous partial hepatectomy. Twenty-
eight (19%) received a live, donor-related liver transplant, and 119 (81%) received a de‐
ceased donor liver graft. Median follow up since diagnosis for surviving patients was 38
months (range 1– 121 months). Overall disease-free survival at 6 years post-transplant was
82% and 30% for primary transplants and for rescue transplants, respectively. Multivariate
statistical analysis showed no difference in regard to gender, age, and lung metastases at
presentation or type of transplant. For primary transplants, the only parameter significantly
related to overall survival was macroscopic venous invasion (P = 0.045). Remarkably, the 6-
year, disease-free survival (82%) for the 106 patients who received a primary transplant was
similar to the 3-year, progression-free survival (89%) for the 77 HB patients with standard-
risk hepatoblastoma confined to the liver and involving no more than 3 hepatic sections that
were enrolled in the SIOPEL-2 study. [67] In a recent review of the UNOS database in the
USA concerning liver transplantation in 135 children transplanted for unresectable or recur‐
rent HB (1987–2004), the one, five, and 10-year survival was 79%, 69%, and 66% respectively.
[78] The median age at transplantation was 2.9 ± 2.5 years. Sixteen percent received a graft
from a live donor. Fifty-five percent of the deaths were due to metastases or recurrent dis‐
ease. The latest ELTR report, including 129 patients transplanted for HB has shown a 1- and
5-year survival of 100% and 74%, respectively. [55, 79]
3.6. Timing of transplantation
Timing of liver transplantation should not be delayed in excess of a few weeks after the last
course of chemotherapy (as per protocol). An expeditious access to organ donors is required
to meet this requirement. If this is not possible with deceased donors (including split liver
grafts), a live-related donor is a valuable option. [55]
According to the results of published studies, the following guidelines have been developed
for early consultation with a transplant surgeon: [55]
1. Multifocal PRETEXT IV HB is a clear and undisputed indication for primary liver trans‐
plantation, whatever the result of chemotherapy. Apparent clearance of one liver lobe
should not distract from this guideline because of the high probability of persistent mi‐
croscopic viable neoplastic cells. Pediatric oncologists should resist the temptation to in‐
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tensify chemotherapy in a vain effort to avoid transplantation. These patients should be
treated within the same protocol as patients with localized tumors amenable to partial
hepatectomy, with as many cycles of chemotherapy before and after transplantation as
patients submitted to partial hepatectomy for a localized HB.
2. Primary liver transplantation may be the best option for large, solitary PRETEXT IV
HB,  involving  all  four  sections  of  the  liver,  unless  tumor  downstaging  is  clearly
demonstrated after  initial  chemotherapy.  If  this  is  the case,  a  clear  retraction of  the
tumor from the anatomic border of one lateral sector would allow performance of a
radical trisegmentectomy.
3. Unifocal, centrally located PRETEXT II and III tumors involving main hilar structures
or all three main hepatic veins should be considered for primary liver transplantation
because these venous structures would presumably not become free of tumor after che‐
motherapy. Heroic attempts at partial hepatectomy would be best avoided because of
the risk of incomplete resection of malignant tissue.
3.7. Contraindications
Persistence of viable extrahepatic tumor deposit after chemotherapy, not amenable to surgi‐
cal resection, is the only absolute contraindication for liver transplantation. Macroscopic ve‐
nous invasion (portal vein, hepatic veins, vena cava) is not a contraindication if complete
resection of the invaded venous structures can be accomplished. When there is evidence or
suspicion of invasion of the retrohepatic vena cava, it should be resected ‘‘en-bloc” and re‐
constructed. Review of the world experience showed that venous extent was associated with
a significantly shorter survival (P = 0.045). [77] Of the nine TNM IV A/IVB patients (eight
with major intrahepatic venous invasion) reported by Reyes and associates, seven were alive
and disease-free 21–146 months after transplantation. [80]
Patients with lung metastases at presentation should not be excluded from liver transplanta‐
tion if the metastases clear completely after chemotherapy and/or surgical resection. Long-
term, disease-free survival was obtained in 80% of such patients in the SIOPEL-l study and 58%
in the world experience. Complete eradication of metastatic lesions by chemotherapy and sur‐
gical resection of any suspicious remnant after chemotherapy is a paramount pre-requisite for
transplantation. [81] When tumor resection by partial hepatectomy is incomplete or when in‐
trahepatic relapse is observed after a previous partial hepatectomy, performing a rescue liver
transplantation may be a relative contraindication because of the disappointing results ob‐
served in the SIOPEL-l study and in the reported world experience. [55]
3.8. Outcomes
In experienced surgical units, major intraoperative complications of liver resection for HB
such as severe bleeding, air embolism, and unrecognized bile duct injury are infrequent and
operative mortality is very low, even after extended hepatectomies, since children with HB
have no underlying liver disease. As an example, summarizes the 25 years (1978–2003) of
experience gained at Cliniques Saint-Luc, Brussels [82] with 53 children treated for HB.
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There were 39 partial hepatectomies, including 23 right or left trisegmentectomies, and 13
primary liver transplants (two from deceased donors and 11 from living related donors).
Only one child died from surgical complications (extensive portal vein thrombosis present
at diagnosis). Postoperative bleeding requiring reoperation was encountered in 2 patients
(3.5%). The incidence of biliary complications was 7.6% after partial hepatectomy and 23%
following liver transplantation. Actuarial disease-free survival was 89% and 79% in trans‐
plant patients and in children treated with partial hepatectomy, respectively. [55]
Although individual centers treat relatively small numbers of patients with liver cancer, the
best overall survival rates are obtained in experienced units that include liver transplanta‐
tion in their surgical armamentarium. [55, 83, 84, 85]
The most recent report from King’s college, London [86] confirms that the modern strategy
of combining chemotherapy and radical tumor resection enables the majority of children
with HB to be cured. From October 1993 to February 2007, 25 liver transplantations were
performed for HB: 18 from deceased donors and 7 from living donors. Fifteen and ten pa‐
tients were PRETEXT IV and III, respectively. All patients received preoperative chemother‐
apy following the successive SIOPEL protocols. Patient and graft survival after cadaveric
transplantation was 91%, 77.6% and 77.6% after 1, 5 and 10 years, respectively, without re‐
transplantation. Patient and graft survival after living related liver transplantation was
100%, 83.3% and 83.3%, respectively. All surviving children but one remain disease-free,
with a median follow up of 6.8 years (range: 0.9–14.9). There were five deaths at a median of
13 months post-OLT, secondary to tumor recurrence in 4 and respiratoryfailure in one. [55]
A remote data entry system is accessible online, worldwide, and free of charge. Registration
is open for patients transplanted since January 1st, 2006 (http://www.pluto.cineca.org). PLU‐
TO stands for Pediatric Liver Unresectable Tumor Observatory and was developed by the
SIOPEL strategy group. This will allow online registration of children undergoing liver
transplantation for a malignant liver tumor. The aim is to establish an international multi‐
center database with prospective registration of children (<18 years) presenting with unre‐
sectable tumor (HB, HCC, epithelioid hemangioendothelioma and other rare malignant
tumors) undergoing primary orrescue liver transplantation.
4. Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) in childhood is rare and accounts for less than 0.5% of all
pediatric malignancies, [87, 88] is the second most common malignant hepatic neoplasm in
children. HCC presents at an older age than does hepatoblastoma, with most HCC cases di‐
agnosed in children older than 5 years. [89] Its relative frequency is 0.5 to 1.0 cases per mil‐
lion children. It is more frequently encountered in older children and teenagers than in
infants. [88,90] HCC is more often encountered in males and older children between age 10
and 14 yr and the median age of onset is 12 year. [88]
Previous reports from Southeast Asia cite an annual incidence of pediatric hepatic tumors
that is roughly four times higher than western reports in children with less than 15 years of
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age. [91] This finding is largely based on the high hepatitis carrier rate, with a Taiwanese
report stating that 80% of primary liver tumors in children were hepatocellular carcinoma.
With the introduction of hepatitis B vaccine in Southeast Asia, however, there has been a
marked reduction in the incidence of hepatocellular carcinoma, although the impact of the
hepatitis B vaccine has mainly reduced the incidence of liver tumors in males. [92] Occasion‐
ally, malignant tumors in children are seen with features of both hepatocellular carcinoma
and hepatoblastoma. These tumors are more common in children with a diagnosis at later
ages than that typical of hepatoblastoma.
There is an association with pediatric HCC and pre-existing liver cirrhosis, most often because
of biliary atresia, Fanconi’s syndrome, and hepatitis B. However, most pediatric HCC are de
novo tumors and are not necessarily related to cirrhosis. [75] In certain metabolic diseases such
as hereditary tyrosinemia and glycogen storage disease type IA, there is an increased inci‐
dence of HCC. Hereditary tyrosinemia, caused by a deficiency in fumarylacetoacetate hydro‐
lase, results in a greatly increased susceptibility to HCC. This is because of the accumulation of
toxic metabolites in the liver, and the incidence of HCC is 50% by age two. Current medical
therapies for tyrosinemia markedly reduce but do not eliminate the risk of development of
HCC. Glycogen storage disease type IA is caused by a deficiency in glucose- 6-phosphatase.
This results in the development of hepatic adenomas in 50% of patients, and about 11% of pa‐
tients with adenomas because of glycogen storage disease type IA will undergo malignant
transformation into HCC. [93] Other risk factors for HCC include previous treatment with an‐
drogenic steroids, oral contraceptives and methotrexate. [94] Unlike adult HCC, pediatric
HCC often demonstrate reduced levels of cyclin D1 expression. [95] Whether this is involved
in the pathogenesis of pediatric HCC is still unclear. [96]
HCC is a malignancy of hepatocyte origin. The tumor is noted to have a fibrous capsule and
is also predisposed to vascular invasion. [97] There are two distinct groups of HCC patients
in childhood: those developing HCC in the context of advanced chronic liver disease (CLD),
and children who develop sporadic HCC without preceding liver disease. The latter group
typically affects older children. Their clinical behavior and biologic behavior are similar to
HCC in adults. Approximately 26% of cases are histologically of a fibrolamellar type, [98]
which does not appear to make a prognostic difference. Sporadic HCC in children has a rel‐
atively poor outcome, [75] while the several small series that report on HCC developing in
CLD do so in the context of liver transplantation (LT) [82, 99, 100, 101, 102] The fibrolamellar
subtype of HCC (FLHCC) accounts for 3% of HCCs and is not associated with underlying
liver disease. FLHCC lesions are solitary, encapsulated, and well defined. Up to 75% of pa‐
tients will have elevated serum AFP levels. [89, 97].
As for the pathology, HCC macroscopically are usually multifocal and invasive, commonly
involving both lobes and frequently associated with vascular invasion, extrahepatic exten‐
sion, or both at the time of diagnosis. Areas of hemorrhage and necrosis are common, and
the lesions themselves vary in consistency from soft to firm. This significantly reduces the
resectability rate. Czauderna et al report only a 36% complete tumor resection rate in a series
of 39 children recorded by the International Society of Pediatric Oncology over a 4-year time
period. [75] The microscopic features distinguishing hepatocellular carcinoma from hepato‐
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blastoma are the presence of tumor cells larger than normal hepatocytes, broad cellular tra‐
beculae, considerable nuclear pleomorphism, nucleolar predominance, frequent tumor giant
cells, and absence of hemopoiesis. [33,94] The fibrolamellar variant of HCC is probably a
separate clinical entity. Histologically, the tumor cells are plump, with deeply eosinophilic
cytoplasm and a marked fibrous stroma separating epithelial cells into trabeculae. [103]
HCC often present as abdominal swelling associated with dull aching pain and discomfort.
Other frequent complaints are of rapid weight loss and weakness. [75] The most common
clinical sign is hepatomegaly. HCC frequently presents at the time of diagnosis with meta‐
static spread, most commonly to the regional lymph nodes, lungs and bones. [96]
4.1. Laboratory findings
Although most children with HB have an elevated serum AFP level, this marker is elevated
in 50–70% of patients with HCC and less markedly than in HB. Approximately 60–80% of
HCC present with significantly elevated AFP levels. [96] All children with HCC should be
screened for exposure to viral hepatitis B and C. Similar to HB, some children with HCC
may be anemic and others may demonstrate thrombocytosis. Children with cirrhosis-associ‐
ated HCC may present with elevated serum liver enzyme levels (AST) and those with sple‐
nomegaly may show pancytopenia. Careful assessment of hepatic functional reserve in
children with cirrhosis is important prior to embarking on major hepatic resection. Howev‐
er, no specific data are available for children regarding tests used in adults (Iodocyanine-
green (ICG) dye clearance, galactose elimination capacity). Therefore, the evaluation of the
hepatic functional reserve in children is based on standard liver tests including total biliru‐
bin, prothrombine time and INR. [55]
4.2. Imaging
The diagnostic imaging in children with HCC is not different from HB. HCC is often multi‐
focal and may present with a variable number and distribution of tumor nodules. While
identifying larger nodules is not difficult, recognizing lesions less than 1.0 cm is still a chal‐
lenge. Positron emission tomography (PET) using 18- fluorodeoxyglucose may be useful in
identifying unsuspected extrahepatic disease. [104]
Three-dimensional CT image analysis techniques are now available to estimate tumor vol‐
ume and provide detailed intrahepatic anatomy that resembles the actual intraoperative
findings. CT volumetry may permit calculation of resected tumor volume and anticipated
size of the remnant liver in planning resection. [105] Diagnostic laparoscopy is useful to de‐
termine if extra- hepatic disease is present and may avoid unnecessary attempts at resection.
Plain radiograph and CT of the chest should be obtained to rule out lung metastases. Hepat‐
ic arteriography is currently limited to instances of HCC managed by hepatic artery infusion
or transcatheter chemoembolization which can be performed in older children. [55]
On US imaging, HCC may appear as a solitary or multicentric mass most commonly involv‐
ing the right lobe of the liver, or as a diffusely infiltrating lesion. At diagnosis, these masses
appear solid, rarely contain calcification, and have variable echogenicity. Small lesions ap‐
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pear homogeneous and are most often hypoechoic. The capsule can be seen as a hypoechoic
halo. Larger lesions become necrotic, and therefore demonstrate a more heterogeneous ap‐
pearance. Doppler US may detect the high-velocity flow that is related to neovascularity, but
Doppler US is most useful for identifying venous invasion. Portal venous invasion is identi‐
fied in up to 60% of cases, [106] with hepatic venous invasion identified less commonly.
Doppler US may differentiate neoplastic thrombus from bland (benign) thrombus by detect-
ing internal neovascularity in the former. [97]
Potentially curative therapies can treat the very early and early stages of the disease. How‐
ever, less than 30% of HCC patients are detected with the disease in those stages. [107] An‐
other 20% of patients with terminal stage HCC receive recommendations for the best
supportive treatment. Since HCC is unresectable in the majority of patients at the time of the
first diagnosis, patients are often directed to nonsurgical treatments. Physicians have long
overlooked radiotherapy (RT) for HCC as radiation might induce fatal hepatic toxicity at
doses lower than the therapeutic doses. [108] However, such limitation has been overcome
by recent developments in RT technology involving precise delivery of focused high-dose
on partial volume of the liver. [109, 110, 111, 112, 113, 114] According to the Korean Liver
Cancer Study Group (KLCSG) practice guidelines, RT is considered appropriate for unre‐
sectable, locally advanced HCC without extrahepatic metastasis, Child-Pugh class A or B,
and tumors occupying less than two-thirds of the liver. [115]
4.3. Results of resection
Based on recent experience, the optimal treatment should have been total hepatectomy and
liver transplantation. Katzenstein et al. reported on 46 children enrolled in the POG and
CCG studies - 8 with stage I, 25 with stage III, 13 with stage IV. [49] The overall event-free
survival at 5 years was 17%. The outcome was not more favorable in 10 children with FL-
HCC. No difference in survival was observed whatever the chemotherapy regimen was giv‐
en. 369 The German Cooperative Liver Study Group [116] reported the results of two
prospective trials. The survival rate of HCC was 33% and 25% in HB-89 (12 patients – 1989–
1993) and 25% in HB-94 (25 patients – 1994–1998), respectively. The SIOPEL-1 study (1990–
1994) enrolled 39 patients with HCC who were treated with neoadjuvant chemotherapy
(PLADO). Thirty-one percent had metastases, 39% had extrahepatic extension/vascular inva‐
sion, 56% had multifocal HCC while 31% had pre-existing liver disease. A partial response
to PLADO was observed in 49%, a complete tumor resection was possible in 36% (2 with
liver transplantation). The 5-year event-free survival was 17%. Adverse prognostic factors
included multifocality, metastases and vascular invasion. In SIOPEL-2 pilot study (1994–
1998), 21 patients were treated with ‘‘super-PLADO” (carboplatin, cisplatin and doxorubi‐
cine). Eighteen percent had metastases, 35% had extrahepatic extension/vascular invasion
and 53% had multifocal HCC. Partial response to SUPER-PLADO was observed in 46%;
complete tumor resection was performed in 47% (one with liver transplantation). The 3-year
overall survival was 22%. In SIOPEL-3 (1999–2004), 65 patients were treated with SUPER-
PLADO with a partial response in 40%. Thirteen underwent primary surgery. Forty-four
percent were never resectable. The 3-year event-free survival was 10%. Currently, the new
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SIOPEL-5 study is evaluating non-cirrhotic HCC patients staged according to the PRETEXT
system and receiving neoadjuvant PLADO chemotherapy and thalidomide (an anti-angio‐
genic agent) followed by surgery and postoperative metronomic chemotherapy.
4.4. Liver transplantation for hepatocellular carcinoma
Experience with liver transplantation in children with unresectable HCC is somewhat limit‐
ed but results have significantly improved over the recent years. Beaunoyer et al. reported
on 10 children with underlying liver disease in 5 and cirrhosis in 5. Six had one nodule >5
cm and 7 had >3 nodules. The 5-year actuarial survival was 83%; two died, one of recur‐
rence, while 2 with macrovascular invasion survived. Number and size of lesions or gross
vascular invasion did not significantly impact survival. [82] Reyes et al. reported on 19 chil‐
dren with HCC who underwent total hepatectomy and liver transplantation in 1989–1998;
two thirds had underlying liver disease. [80] The 5-year disease-free survival was 63% (3/6
died of recurrent HCC). In their experience, risk factors for recurrence were tumor size, vas‐
cular invasion and lymphnode involvement. [80] Austin et al. analyzed the aggregated out‐
come for OLT in HCC in 41 children <18 years (UNOS data). Patient survival was 63% at 5
year and 58% at 10 year. Recurrence was the primary cause of death in 86%. [78]
The most conventional criteria for transplantation are the so-called Milan criteria: [117] no
more than three tumors, each not more than 3 cm in size, or a single tumor, not more than 5
cm in diameter, and no evidence of extrahepatic disease or vascular invasion. Recent studies
suggest that, in an otherwise normal liver, the present cut-off for tumor size might be ex‐
panded to 6.5 cm or 7 cm. [118, 119] The evidence supports the moderate expansion of the
Milan criteria although findings from different studies lack consistency and prospective val‐
idation by pretransplant imaging. [79] There are no hard data implying that Milan criteria
can appropriately select children with a low risk of recurrence of HCC after transplantation.
Indeed, Milan criteria are derived from experience in adults with cirrhosis, whereas the ma‐
jority of children with HCC have no underlying cirrhosis. There is no prospective trial in
children while the role of OLT in non-cirrhotic liver is unknown. Moreover, there are differ‐
ences in biology [120] between adult and pediatric HCC with different molecular findings:
mutation of c- met gene in children with HCC, not in adults, level of glycin D1 (regulatory
protein of G1 phase cycle) expression is lower in children, loss of heterozygosity on chromo‐
somal arm, 13q, higher in children. There is evidence that childhood HCC might be less che‐
moresistant than adult HCC; a partial response was observed in 49% enrolled in SIOPEL-1
study. [75] The SIOPEL group has launched in 2005 a new SIOPEL-5 trial directed to non-
cirrhotic hepatocellular carcinoma in children and adolescents. It is based on the hypothesis
that the addition of an antiangiogenic drug (Thalidomide) to PLADO will result in an im‐
provement of survival with acceptable toxicity. Most likely, Sorafenib will be substituted for
Thalidomide on the basis of data obtained in adults with advanced HCC. [121]
Patients with unresectable disease restricted to the liver will be submitted to liver transplan‐
tation. Since the majority of children with HCC in western countries have no underlying liv‐
er disease, recent data suggest that liver transplantation may be quite useful treatment in
carefully selected unresectable cases. [78, 80, 82] Unlike the adult population, the frequency
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of HCC in the pediatric population is low; therefore, the experience in the application of liv‐
er transplantation in the pediatric population for HCC is limited. [122, 123, 124, 125] In pa‐
tients whose disease is confined to the liver, the use of liver transplantation is indicated.
Because chemotherapy is not beneficial at present in this group, results in patients with
more extensive disease are poor. [126]
5. Benign tumors
In general, benign tumors of the liver may arise from hepatocytes, bile duct epithelium, the
supporting mesenchymal tissue, or a combination of two or more of these. In addition to
true neoplastic conditions of the liver, a variety of nodular diseases may occur that resem‐
ble, and must therefore be differentiated from, tumours. Although most patients with be‐
nign hepatic tumors are asymptomatic, a minority may present with symptoms that may be
local or systemic. In these patients, the relationship between the symptoms and the hepatic
lesions may be difficult to correlate, and additional evaluation is necessary to rule out other
causes for the patients complaints. In most cases patients with benign hepatic lesions have
no preexisting liver disease, and the finding of a coexisting chronic liver disease such as cir‐
rhosis, chronic hepatitis B or C, or hemochromatosis should raise a suspicion for a malig‐
nant tumor. A conclusive diagnosis of a focal hepatic lesion is essential because it may
represent a primary or secondary malignancy, which may require immediate treatment. In
addition, some benign lesions carry specific risks such as rupture, bleeding, malignant trans‐
formation, consumptive coagulopathy, and disseminated intravascular coagulation. [127]
Primary liver masses constitute the third most common group of solid abdominal tumors of
childhood, [2, 128, 129] with an incidence of 0.4 to 1.9 per million children each year. [129,
130] Benign primary liver masses described in children include hemangioma/infantile hep‐
atic hemangioendothelioma, focal nodular hyperplasia, simple hepatic cysts, mesenchymal
hamartomas, adenomas, nodular regenerative hyperplasia, hematomas, arterial venous mal‐
formations, granulomas, and lymphangiomas. [2, 12, 128, 129, 130, 131, 132, 133]
Infantile hepatic hemangioendothelioma is a tumor derived from vascular endothelial cells,
which is the most diagnosed benign hepatic tumor in children. Hence it accounts for ap‐
proximately 12% of all childhood hepatic tumors,the most common benign vascular tumor
of the liver in infancy, and the most common symptomatic liver tumor during the first 6
months of life. [134, 135, 136, 137]
While the majority of benign masses may be of little consequence, morbidity and mortality
can occur from benign masses, mass effect from a tumor can cause pain, biliary obstruction
and inferior vena cava obstruction, limit lung capacity, or cause feeding difficulty. [2, 12,
129, 138] Most of the recent radiology literature concerning the liver has focused on lesions
detection or identification of specific features (enhancement patterns) that may help distin‐
guish benign from malignant hepatic tumours. Except for hemangioma and focal nodular
hyperplasia (FNH), little is know about imaging characteristics that can help identify and
distinguish among the many less common bening liver masses. [139]
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5.1. Infantile hepatic hemangioendothelioma
More than 90% are diagnosed before the age of 6 years. The typical presentation is of hepa‐
tomegaly, hemangiomas of the skin, and heart failure resulting from massive arteriovenous
shunting. [127, 140] In addition to heart failure, this tumor may cause consumption coagul‐
opathy (Kasabach–Merritt syndrome) and obstructive jaundice. [127, 141] Although well cir‐
cumscribed, this tumor is not encapsulated and often has scattered calcifications.
Microscopically, this tumor consists of multiple small vessels lined by plump endothelial
cells and surrounded by fibrous stroma.
Ultrasonography usually shows hepatomegaly and solitary or multiple hepatic lesions,
which may vary from anechoic to hyperechoic. The unenhanced CT scan demonstrates the
lesion as a well-defined hypo-attenuating mass, occasionally with calcifications. After con‐
trast injection, the lesion may show enhancement resembling hemangioma and may become
isodense on delayed images. Angiography shows dilated, irregular vascular lakes that com‐
monly persist beyond the venous phase. 99mTc-sulfur colloid scintigraphy shows the lesion
as a cold spot because of a lack of Kupffer cells within the tumor. [127]
The prognosis of this lesion is dependent on its size and its effect on the heart function.
Spontaneous regression is frequent but death may occur within the first 6 months of life be‐
cause of cardiac failure or replacement of the normal hepatic parenchyma. [127, 142] The
prognosis is usually good if heart failure is managed successfully.
Treatment is dictated by tumor-related symptoms produced by tumor size. Management of
congestive heart failure may be sufficient in some cases. If symptoms are not relieved, treat‐
ment should be aimed at decreasing the tumor size. [127]
Other treatments include hepatic artery ligation, transcatheter endovascular embolization,
and radiation therapy. [127, 143, 144] Liver transplant is increasingly recognized as a viable
treatment modality for infantile hemangioendothelioma when other treatments fail. [127, 145]
5.2. Focal Nodular Hyperplasia (FNH)
FNH is very rare in pediatric population with an age prevalence in children 7-8 years old,
although  some  cases  are  diagnosed  in  early  childhood  or  even  in  the  prenatal  period.
[146, 147] The female sex is predominant with a M/F ratio of less than 1/10 in one of the
largest series. [147, 148]
The majority (70-90%) of FNH at presentation is asymptomatic and the most common way
that the disease is discovered is when, during an occasional physical examination, hepato‐
megaly or a palpatory abdominal mass are detected. The lesion is more often unique, but
about 8% of cases may show multiple nodules, up to 30. The diameter of lesions is extremely
variable, from less than 1 cm to more than 15 cm but usually is less than 5 cm. [147]
The diagnosis in the majority of cases could be by Ultrasound, CT Scan and MRI. Needle
biopsy or open air biopsy are necessary when the radiological investigations are doubtful,
above all in case of absence of the central scar, and not rarely the differential diagnosis from
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other nodular lesions of liver may be difficult. The differential diagnosis includes different
nodular lesions of the liver. [147]
The natural evolution of FNH is unpredictable. In about 2/3 of cases, remain stable and in
about 1/3-1/4 of cases show a gradual spontaneous improvement as far as a complete remis‐
sion. In rare instances an increase in number as well as in size may occur [9]. The recent studies
in molecular biology have confirmed that FNH is not a pre-neoplastic lesion: the tissue paren‐
chymal organization is pretty the same of usual liver tissue and, moreover, even though in
some cases a clonal origin of FNH nodules have been demonstrated, until now no somatic mu‐
tation in the β-catenin gene or in the other genes implicated in the hepatocellular adenoma
(where a malignant transformation is possible) have been discovered. [147, 149, 150]
About the management the first step is, of course, the stop of oral contraceptive. Considering
the body of evidence that FNH doesn't undergo malignant transformation and that there are
only sporadic cases followed by spontaneous rupture and consequent abdominal bleeding, we
agree with the opinion that in asymptomatic cases it is opportune a careful follow-up with an
ultrasound scan every 6-12 months, and that elective surgery has probably to be limited to the
patients suffering of abdominal pain or with a voluminous or growing mass. [147, 149]
5.3. Nodular regenerative Hyperplasia (NRH)
Nodular regenerative hyperplasia (NRH) is a disease characterized by multiple nodules
composed by hepatocytes, without a fibrous tissue or central scar. The rare pediatric cases
are mostly in association with the congenital absence of portal vein (sometimes complicated
by heart disease or multi-cystic kidney dysplasia). Indeed, only about 200 cases have been
reported. Symptoms, when present, are mainly associated with the complication of portal
hypertension. [151, 152, 153, 154]
CT presentation is really different from FNH, as there are multiple hypodense lesions with
poor or absent enhancement after contrast administration. [147, 155] The typical imaging
showing anechoic and regular profile of the mass at ultrasound, easily recognize cystic le‐
sions: however CT and MRI may be necessary in selected cases. [147]
5.4. Hamartomas
Mesenchymal hamartoma is a rare, benign, developmental tumor of the liver, with occasion‐
al risk of malignancy. Histologically, it appears as a disordered arrangement of the mesen‐
chyme, bile ducts, and hepatic parenchyma. Cords of normal appearing hepatocytes are
separated by zones of loose, poorly cellular mesenchyme. The porous nature of the mesen‐
chyme permits accumulation of fluid. [156, 157] Grossly, it has stromal and cystic compo‐
nents with no capsules, and can grow to large sizes. [157, 158] The typical presentation is
one of asymptomatic, rapid abdominal distention with a palpable mass on physical exami‐
nation. The rapid expansion of the tumor is believed to be due to degeneration of the mesen‐
chyme and fluid accumulation. Other uncommon associated symptoms are vomiting, fever,
constipation, diarrhea, and weight loss. [156, 157] Laboratory investigations usually reveal
normal liver function with elevated alpha-fetoprotein, which is believed to be secreted by
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the proliferating hepatocytes within the tumor. [157, 159] The radiological appearance is one
of a large, uni or multi-cystic, avascular mass occupying part of the liver. [157, 158] Surgical
resection has been the standard treatment for this tumor.
6. Sarcoma
The third most common hepatic malignancy, after hepatoblastoma and hepatocellular carci‐
noma, is undifferentiated embryonal sarcoma. [8, 160, 161] It is believed to be a primitive
mesenchymal neoplasm, which usually behaves in a highly malignant fashion. [162] It was
first recognized as a clinicopathologic entity by Stocker and Ishak in 1978. [156] Before their
report, this tumor had been described under different names such as embryonal sarcoma
[163] mesenchymoma, [164] primary sarcoma [165] or fibromyxosarcoma. [166]
These tumors occur in children 5–10 years of age and are mesenchymal in appearance. [8, 167]
Diagnosis of primary hepatic sarcoma is challenging due to the lack of specific presenting
symptoms, lack of serological markers, non-specific findings on radiological imaging and the
rarity of the disease. [86] However, leukocytosis and elevated aspartate aminotransferase and
alkaline phosphatase are not uncommon laboratory findings. [156, 161, 162, 168, 169] The se‐
rum α-fetoprotein level is always normal. [156, 161, 162, 169] There is no correlation with hepa‐
titis B or C virus infection. Most tumors have prominent areas of cystic degeneration. [161, 162]
Multinucleated giant tumor cells with eosinophilic cytoplasm and frequent mitosis are usually
present. (Stocker and Ishak,1978 and [162] et al.,2001) PAS-positive, diastase-resistant hyaline
globules, which are believed to be lysosomes or apoptotic bodies, are frequently seen within
tumor cells as well as in extracellular stromata. [156, 162, 168, 170, 171]
Regarding the radiological imaging, undifferentiated embryonal sarcoma often show a mis‐
leading cystic appearance on CT and magnetic resonance imaging (MRI) in contrast to a pre‐
dominantly solid appearance on ultrasound. [86, 172]
Undifferentiated embryonal sarcoma of the liver behaves in a highly malignant fashion, [162,
173] and the median survival has been less than a year. [156, 162] Complete surgical resection is
the key to a favorable outcome. However, despite apparent complete resectability in somecas‐
es, local recurrence and distant metastases have been major impediments to achieving long-
term  disease-free  survival.  [162,  173]  Multidisciplinary  treatment  (chemotherapy  and
radiotherapy) has been used to achieve superior and local control and disease-free survival in
patients with Undifferentiated embryonal sarcoma of the liver. [160, 167, 173]
Author details
Julio C. Wiederkehr1,2*, Izabel M. Coelho1,2, Sylvio G. Avilla1,2, Barbara A. Wiederkehr2 and
Henrique A. Wiederkehr2
*Address all correspondence to: julio.wieder@uol.com.br
Hepatic Surgery446
1 Federal University of Paraná, Curitiba, Brazil
2 Hospital Pequeno Príncipe, Curitiba, Brazil
References
[1] Kim, E. H., Koh, K. N, Park, M, Kim, B. E, Im, H. J, & Seo, J. J. (2011). Clinical features
of infantile hepatic hemangioendothelioma. Korean Journal of Pediatrics, 54(6), 260,
doi:10.3345/kjp.2011.54.6.260.
[2] Luks, F. I., Yazbeck, S., Brandt, M. L., et al. (1991). Benign liver tumors in children: a
25- year experience. J Pediatr Surg, 26, 1326-30.
[3] Reymond, D., Plaschkes, J., Luthy, A. R., et al. (1995). Focal nodular hyperplasia of
the liver in children: review of follow-up and outcome. J Pediatr Surg, 30, 1590-3.
[4] Ehren, H., Mahour, G. H., & Isaacs, H., Jr. (1983). Benign liver tumors in infancy and
childhood. Report of 48 cases. Am J Surg, 145, 325-9.
[5] Emre, S., & Mc Kenna, G. J. (2004). Liver tumors in children. Pediatric transplantation,
8(6), 632-8.
[6] Weinberg, AG, & Finegold, MJ. (1983). Primary hepatic tumors of childhood. Hum
Pathology, 14, 512-537.
[7] Multerys, M., Goodman, M. T., Smith, MA, et al. (1999). Hepatic Tumors. In Ries
LAG, SmithMA,GurneyJGet al. (eds). Cancer Incidence, SurvivalamongChildren,
Adolescents: United States SEER Program 1975-1995. SEER Program, NIH Pub.
[99-4649], Bethesda, MD, National Cancer Institute, 91-97.
[8] Litten, J. B., & Tomlinson, G. E. (2008). Liver tumors in children. The oncologist, 13(7),
812-20.
[9] Dimmick, J. E., Rogers, P. C. J., & Blair, G. (1994). Hepatic Tumors. In: Pochedly C, ed.
Neoplastic Siseases of Childhood, Chur, Switzerland, Harwood Academic, 973-1010.
[10] Kelly, D. (2008). Diseases of the Liver and Biliary System in Children ed., Wiley-Black‐
well, Oxford.
[11] Kenney, LB, Miller, B. A., Ries, L. A., et al. (1998). Incidence of cancer in infants in the
U.S.: 1980-1990. Cancer, 82, 1396-1400.
[12] Meyers, R. L. (2007). Tumors of the liver in children. Surgical oncology, 16(3), 195-203.
[13] Mann, J. R., Kasthuri, N., Raafat, F., et al. (1990). Malignant hepatic tumours in chil‐
dren: incidence, clinical features and aetiology. Paediatr Perinat Epidemiol, 4, 276-289.
Liver Tumors in Infancy
http://dx.doi.org/10.5772/51764
447
[14] Bulterys, M., Goodman, M. T., Smith, M. A., et al. (1999). Cancer Inci- dence and Sur‐
vival Among Children and Adolescents: United States SEER Program1975-1995. Na‐
tional Cancer Institute SEER Program. NIHPublication [99-4649], 91-97.
[15] Owe, T., Kubota, A., Okuyama, H., et al. (2003). Hepatoblastoma in children of ex‐
tremely low birth weight: a report from a single prenatal center. Journal of Pediatric
Surgery, 38, 134-7.
[16] Honda, S., Haruta, M., Sugawara, W., et al. (2008). The methylation status of
RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in
hepatoblastoma patients. Int J Cancer, 5, 1117-25.
[17] Sakamoto, L. H., De Camargo, B., Cajaiba, M., et al. (2010). MT1G hypermethylation:
a potential prognostic marker for hepatoblastoma. Pediatr Res, 67, 387-93.
[18] Exelby, P. R., Filler, R. M., & Grosfeld, J. L. (1975). Liver tumors in children in the
particular reference to hepatoblastoma and hepatocellular carcinoma: American
Academy of pediatrics surgical section survey- 1974. Journal of pediatric surgery, Saun‐
ders, Retrieved from, http://linkinghub.elsevier.com/retrieve/pii/0022346875900950?
showall=true.
[19] DeBaun, M. R., & Tucker, M. A. (1998). Risk of cancer during the first four years of
life in children from the Beckwith-Wiedemann Syndrome Registry. J Pediatr, 132,
398-400.
[20] Steenman, M., Westerfeld, A., & Mannens, M. (2000). Genetics of Beckwith-Weide‐
mann Syndrome associated tumours: common genetic pathways. Genes Chromosomes
Cancer, 28, 1-13.
[21] Giardello, F. M., Offerhaus, G. J., Krush, A. J., et al. (1991). Risk of hepatoblastoma in
familial adenomatous polyposis. J Pediatr, 119, 766-768.
[22] Aretz, S., Koch, A., Uhlhaas, S., et al. (2006). Pediatric Blood Cancer, 47, 811-8.
[23] Hirschman, B. A., Pollock, B. H., & Tomlinson, G. E. (2005). The spectrum of APC
mutations in children with hepatoblastoma from familial adenomatous polyposis
kindreds. Journal of Pediatrics, 147, 263-6.
[24] Wei, Y., Fabre, H., Branchereau, S., et al. (2000). Activation of B-catenin in epithelial
and mesenchymal hepatoblastomas. Oncogene, 19, 498-506.
[25] Jeng, Y. M., Wu, M. Z., Chang, M. H., et al. (2000). Somatic mutations of B-catenin
play a crucial role in the tumorigenesis of sporadic hepatoblastoma. Cancer, 152, 45-5.
[26] Udatsu, Y., Kusafuka, T., Kuroda, S., et al. (2001). High frequency of beta catenin mu‐
tations in hepatoblastoma. Pediatr Surg Int, 17, 508-512.
[27] Tomlinson, G. E., Douglass, E. C., Pollock, B. H., et al. (2006). Cytogenetic analysis of
a large series of hepatoblastoma: numerical aberrations with recurring translocations
involving 1q12-21. Genes Chromosomes Cancer, 44, 177-84.
Hepatic Surgery448
[28] Ruck, P., Xiao, J. C., Pietsch, T., et al. (1997). Hepatic stem-like cells in hepatoblasto‐
ma: Expression of cytokeratin 7, albumin and oval cell associated antigens detected
by OV-1 and OV-. Histopathology, 31, 324-329.
[29] Ruck, P., & Xiao, J. C. (2002). Stem-like cells in hepatoblastoma. Med Pediatr Oncol, 39,
504-507.
[30] Stocken, J. T. (1994). Hepatoblastoma. Semin Diagn Pathol, 11, 136-143.
[31] Malogolowkin, M. H., Katzenstein, H. M., Krailo, M., et al. (2006). Intensified plati‐
num therapy is an ineffective strategy for improving outcome in pediatric patients
with advanced hepatoblastoma. Journal of Clinical Oncology, 24, 2879-84.
[32] Haas, J. E., Feusner, J. H., & Finegold, M. J. (2001). Small cell undifferentiated histolo‐
gy in hepatoblastoma may be unfavorable. Cancer, 92, 3130-4.
[33] Hass, J. E., Mczynski, K. A., Krailo, M., et al. (1989). Histopathology and prognosis in
childhood hepatoblastoma and hepatocellular carcinoma. Cancer, 64, 1082-1095.
[34] Perilongo, G., & Shafford, E. A. (1999). Liver tumours. Eur J Cancer, 19, 953-958.
[35] Teng, C. T., Daeschner, C. W., Jr., Singleton, E. B., Rosenberg, H. S., Cole, V. W., Hill,
L. L., & Brennan, J. C. (1961). Liver disease and osteoporosis in children. I. Clinical
observations. Journal of Pediatrics, 59, 684-702.
[36] Van Tornout, J. M., Buckley, J. D., Quinn, J. J., et al. (1997). Timing and magnitude of
decline in alpha-fetoprotein levels in tested children with unresectable or metastatic
hepatoblastoma are predictors of outcome: a report from the Children’s Cancer
Group. J Clin Oncol, 15, 1190-1197.
[37] Hartley, A. L., Birch, J. M., Kelsey, A. M., et al. (1990). Epidemiological and familial
aspects of hepatoblastoma. Med Pediatr Oncol, 18, 103-119.
[38] Feusner, J. R., Krailo, M. A., Hass, J. E., et al. (1993). Treatment of pulmonary meta‐
stasis of initial stage I hepatoblastoma in child- hood: report from the children’s can‐
cer group. Cancer, 71, 859-864.
[39] Lack, E. E., Neave, C., & Vawter, G. F. (1982). Hepatoblastoma- A clinical and patho‐
logic study of 54 cases. Am J Suj Pathol, 6, 693-705.
[40] Nickerson, H. J., Silberman, T. L., & McDonald, T. P. (1980). Hepatoblastoma, throm‐
bocytosis and increased thrombopoetin. Cancer, 315-7.
[41] Meyers, R. L., Katzenstein, H. M., Rowland, J. H., et al. (2008). PRETEXT and other
prognostic factors in hepatoblastoma. Pediatric Blood Cancer.
[42] Perilongo, G. (2006). State of the art: Treatment of childhood liver tumors. Geneva,
Switzerland. In: 38th annual meeting of SIOP.
[43] Roebuck, D. J., Olsen, O., & Pariente, D. (2006). Radiological staging in children with
hepatoblastoma. Pediatr Radiol, 36, 176-82.
Liver Tumors in Infancy
http://dx.doi.org/10.5772/51764
449
[44] Roebuck, D. (2008). Focal liver lesion in children. Pediatr Radiol, 38(3), 518-22.
[45] De Campo, M., & De Campo, J. F. (1988). Ultrasound of primary hepatic tumors in
childhood. Pediatric Radiol, 19, 19-24.
[46] Helmberger, J. R., Ros, P. R., Medgo, P. J., et al. (1999). Pediatric liver neoplasms: a
radiology-pathological correlation. Eur Radiol, 9, 1339-1347.
[47] Von Schweiniz, D., Burger, D., Weiner, P., et al. (1992). Therapy of malignant liver
tumors in childhood. An intermittent report of the HB-89 multicenter. Clin Pediatr,
204, 214-220.
[48] Katzenstein, H. M., Krailo, M., Malogolowkin, M. H., et al. (2007, February). Biology
and treatment of children with all stages of hepatoblastoma: COG proposal
AHEP-0731. submitted to CTEP and NCI.
[49] Katzenstein, H. M., Krailo, M., Malogolowkin, M. H., et al. (2002). Hepatocellular car‐
cinoma in children and adolescents: results from the Pediatric Oncology Group and
the Children’s Cancer Group intergroup study. J Clin Oncol, 20(12), 2789-97.
[50] Aronson, D. C., Schnater, J. M., Staalman, C. R., et al. (2005). Predictive value of pre‐
treat- ment extent of disease system in hepatoblastoma: Results from the Internation‐
al Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study. J Clin
Oncol, 23, 1245-1262.
[51] Meyers, R. L., Rowland, J. R., Krailo, M., et al. (2009). Predictive power of pretreat‐
ment prognostic factors in children with hepatoblastoma: a report from the Chil‐
dren’s Oncology Group. Pediatr Blood Cancer, 53(6), 1016-22.
[52] Douglass, E. C., Reynolds, M., Finegold, M., et al. (1993). Cisplatin, vincristine, and
fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin
Oncol, 11(1), 96-9.
[53] Brown, J., Perilongo, G., Shafford, E., et al. (2000). Pretreatment prognostic factors for
children with hepatoblastoma-- results from the International Society of Paediatric
Oncology (SIOP) study SIOPEL 1. Eur J Cancer, 36(11), 1418-25.
[54] http://www.cancer.gov/PublishedContent/MediaLinks/308970.html.
[55] Otte, J. B. (2010). Progress in the surgical treatment of malignant liver tumors in chil‐
dren. Cancer treatment reviews, 36(4), 360-71, Elsevier Ltd.
[56] Czauderna, P., Otte, J. B., Aronson, D. C., et al. (2005). Guidelines for surgical treat‐
ment of hepatoblastoma in the modern era : recommendations from the childhood
liver tumour strategy group of the international society of paediatric oncology (SIO‐
PEL). European Journal of Cancer, 41, 1031-6.
[57] Stringer, M. (2006). Liver tumors. Semin Pediatr Surg, 9, 196-208.
[58] Fuchs, J., Rydzynski, J., Hecker, H., et al. (2002). The influence of preoperative che‐
motherapy and surgical technique in the treatment of hepatoblastoma-a report from
Hepatic Surgery450
the German cooperative liver tumours studies HB-89 and HB-94. Eur J Pediatr Surg,
12, 255-61.
[59] Von Schweinitz, D., Faundez, A., Teichmann, B., et al. (2000). Hepatocyte growth-fac‐
tor- scatter-factor can stimulate postoperative tumor-cell proliferation in childhood
hepatoblastoma. Int J Cancer, 85, 151-9.
[60] Ortega, J. A., Douglass, E. C., Feusner, J. H., et al. (2000). Randomized comparison of
cisplatin/vincristin/5-fluorouracil and cisplatin/doxorubicin for the treatment of pe‐
diatric hepatoblastoma (HB): a report from the Children’s cancer group and the pe‐
diatric oncology group. Journal of Clinical Oncology, 18, 2665-75.
[61] Schnater, J. M., Aronson, D. C., Plaschkes, J., et al. (2002). Surgical view of the treat‐
ment of patients with hepatoblastoma. Cancer, 94, 1111-20.
[62] Malogolowkin, M. H., Katzenstein, H. M., Krailo, M., et al. Redefining the role of
doxorubicin for the treatment of children with hepatoblastoma. Journal of Clinical On‐
cology.
[63] Von Schweinitz, D., & Haberle, B. (2007, March). German liver tumor study: HB 99.
Poland, Gdansk. In: First international symposium childhood hepatoblastoma.
[64] Von Schweinitz, D., Hecker, H., Harms, D., et al. (1995). Complete resection before
development of drug resistance is essential for survival from advanced hepatoblasto‐
ma-a report fro the German cooperative pediatric liver tumor study HB-89. Journal of
Pediatric Surgery, 30, 845-52.
[65] Ortega, J. A., Douglass, E., Feusner, J., et al. (1994). A randomized trial of cisplatin/
vincristine/5-fluorouracil vs. CCP/doxorubicin continuous infusion for the treatment
of hepatoblastoma: results from the pediatric inter-group hepatoma study (abstr).
Proc Am Soc Clin Oncol (ASCO), 13, 416.
[66] Pritchard, J., Brown, J., Shafford, E., et al. (2000). Cisplatin, doxorubicin and delayed
surgery for childhood hepatoblastoma: a successful approach-results of the first pro‐
spective study of the International Society of Pediatric Oncology. J Clin Oncol, 18,
3819-28.
[67] Perilongo, G., Shafford, E., Maibach, R., et al. (2004). Risk-adapted treatment for
childhood hepatoblastoma Final report of the second study of the International Soci‐
ety of Pediatric Oncology- SIOPEL 2. Eur J Cancer, 40, 411-21.
[68] Meyers, R. L., Malogolowkin, M. H., Rowland, J. M., & Krailo, M. (2006, May 27).
Predictive value of the PRETEXT staging system in children with hepatoblastoma. In:
Presented at the 37th annual meeting American Pediatric Surgical Association, Hilton Head,
SC.
[69] Dall’Igna, P., Cecchetto, G., Toffolutti, T., et al. (2003). Multifocal hepatoblastoma is
there a place for partial hepatectomy? Med Pediatr Oncol, 40, 113-6.
[70] Couinaud, C. (1992). The anatomy of the liver. Ann Ital Chir, 63, 693-7.
Liver Tumors in Infancy
http://dx.doi.org/10.5772/51764
451
[71] Wheatley, J. M., Rosenfield, N. S., Berger, L., & La Quaglia, M. P. (1996). Liver regen‐
eration in children after major hepatectomy for malignancy-evaluation using a com‐
puter-aided technique of volume measurement. J Surg Res, 61, 183-9.
[72] Von Schweinitz, D. (2006). Management of liver tumors in childhood. Semin Pediatr
Surg, 15, 17-24.
[73] Otte, J. B., & De Ville de Goyet, J. (2005). The contribution of transplantation to the
treatment of liver tumors in children. Semin Pediatr Surg, 14, 233-8.
[74] Chardot, C., Sant Martin, C., Gilles, A., et al. (2002). Living related liver transplanta‐
tion and vena cava reconstruction after total hepatectomy including the vena cava
for hepatoblastoma. Transplantation, 73, 90-2.
[75] Czauderna, P., Mac Kinley, G., Perilongo, G., et al. (2002). Hepatocellular carcinoma
in children: results of the first prospective study of the international society of pedia‐
tric oncology group. Journal of Clinical Oncology, 20, 2798-804.
[76] Millar, A. J. W., Hartley, P., Khan, D., et al. (2001). Extended hepatic resection with
transplantation back-up for an unresectable tumor. Pediatric Surgery International, 17,
378-81.
[77] Otte, J. B., Pritchard, J., Aronson, D. C., et al. (2004). Liver transplantation for hepato‐
blastoma: Results from the International Society of Pediatric Oncology (SIOP) study
SIOPEL-1 and review of the world experience. Pediatr Blood Cancer, 42, 74-83.
[78] Austin, M. T., Leys, C. M., Feurer, I. D., et al. (2006). Liver transplantation for child‐
hood hepatic malignancy: a review of the United Network for Organ Sharing
(UNOS) database. J Pediatr Surg, 41, 182-6.
[79] Hoti, E., & Adam, R. (2008). Liver transplantation for primary and metastatic liver
cancers. Transplant Int, 21, 1107-17.
[80] Reyes, J. D., Carr, B., Dvorchik, I., et al. (2000). Liver transplantation and chemothera‐
py for hepatoblastoma and hepatocellular cancer in childhood and adolescence. J Pe‐
diatr, 136(6), 795-804.
[81] Perilongo, G., Brown, J., Shafford, E., et al. (2000). Hepatoblastoma presenting with
lung metastases: treatment results of the first cooperative, prospective study of the
International Society of Pediatric Oncology on childhood liver tumors. Cancer, 89,
1845-53.
[82] Beaunoyer, M., Vanatta, J. M., Ogihara, M., et al. (2007). Outcomes of transplantation
in children with primary hepatic malignancy. Pediatr Transplant, 11(6), 655-60.
[83] Pimpalwar, A. P., Sharif, K., Ramani, P., et al. (2002). Strategy for hepatoblastoma
management: transplant versus nontransplant surgery. J Pediatr Surg, 37, 240-5.
[84] Tiao, G. M., Bobey, N., Allen, S., et al. (2005). The current management of hepatoblas‐
toma: a combination of chemotherapy, conventional resection, and liver transplanta‐
tion. J Pediatr, 146, 204-11.
Hepatic Surgery452
[85] Molmenti, E. P., Wilkinson, K., Molmenti, H., et al. (2002). Treatment of unresectable
hepatoblastoma with liver transplantation in the pediatric population. Am J Trans‐
plant, 6, 535-8.
[86] Faraj, W., Mukherji, D., El Majzoub, N., Shamseddine, A., Shamseddine, A., & Kha‐
life, M. (2010). Primary undifferentiated embryonal sarcoma of the liver mistaken for
hydatid disease. World journal of surgical oncology, 8(58).
[87] Moore, S. W., Hesseling, P. B., Wessels, G., et al. (1997). Hepatocellular carcinoma in
children. Pediatr Surg Int, 12, 266-70 .
[88] Bellani, F. F., & Massimino, M. (1993). Liver tumors in childhood: Epidemiology and
clinics. J Surg Oncol, 3, 119-121.
[89] Dubois, J., Garel, L., Russo, P., et al. (1993). Pediatric case of the day. Radiographics,
13, 691-2.
[90] Parkin, D. M., Stiller, C. A., Draper, G. J., et al. (1988). The international incidence of
childhood cancer. Int J Cancer, 42, 511-520.
[91] Chen, J. C., Chang, M. L., Lin, J. N., et al. (2005). Comparison of childhood hepatic
malignancies in a hepatitisBhyper-endemic area. World J Gastroenterol, 11, 5289-5294.
[92] Chang, M. L., Chen, J. C., Lai, M. S., et al. (1997). Universal hepatitis B vaccination in
Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Child‐
hood Hepatoma Study Group. N Engl J Med, 336, 1855-1859.
[93] Howell, R. R., Stevenson, R. E., Ben-Menachem, Y., et al. (1976). Hepatic adenoma in
type I glycogen storage disease. JAMA, 236, 1481-1489.
[94] Weinberg, A. G., & Finegold, M. J. (1983). Primary Hepatic Tumor of Childhood.
Hum Pathol, 14, 512-537.
[95] Kim, H., Lee, M. J., Kim, M. R., et al. (2000). Expression of cyclin D1, cyclin E, cdk4
and loss of heterozygosity of 8p13q 17p in hepatocellular carcinoma. Comparison
study of childhood and adult hepatocellular carcinoma. Liver, 20, 173-178.
[96] Emre, S., & Mc Kenna, G. J. (2004). Liver tumors in children. Pediatric transplantation,
8(6), 632-8.
[97] Varich, L. (2010). Ultrasound of Pediatric Liver Masses. Ultrasound Clinics, 5(1),
137-152, Elsevier Ltd.
[98] Katzenstein, H. M., Krailo, M. D., Malogolowkin, M. H., et al. (2003). Fibrolamellar
hepatocellular carcinoma in children and adolescents. Cancer.
[99] Arikan, C., Kilic, M., Nart, D., et al. (2006). Hepatocellular carcinoma in children and
effect of living-donor liver transplantation on outcome. Pediatr Transplant, 10, 42-7.
[100] Sevmis, S., & Karakayali, H. (2008). Ozc carcinoma in children. Pediatr Transplant, 12,
52-6.
Liver Tumors in Infancy
http://dx.doi.org/10.5772/51764
453
[101] Hadzic, N., Quaglia, A., Portmann, B., et al. (2011). Hepatocellular carcinoma in chil‐
dren with biliary atresia; King’s College Hospital Experience. J Pediatr.
[102] Hadzic, N., & Finegold, M. J. (2011). Liver neoplasia in children. Clinics in liver dis‐
ease, 15(2), 443-62, vii-x., Elsevier Ltd.
[103] Craig, J. R., Peters, R., Edmondson, H. A., & Omata, M. (1980). Fibrolamellar carcino‐
ma of the liver: a tumor of adolescentes and Young adults with distinctive clinicopa‐
thologic features. Cancer, 46, 372-9.
[104] Hain, S. F., & Fogelman, I. (2004). Recent advances in imaging hepatocellular carcino‐
ma: diagnosis, staging and response assessment functional imaging. Cancer J, 10,
121-7.
[105] Shoup, M., Gonen, M., D’Angelica, M., et al. (2003). Volumetric analysis predicts hep‐
atic dysfunction in patients undergoing major liver resection. J Gastrointest Surg, 7,
325-30.
[106] Rumack, C. M., Wilson, S. R., & Charboneau, J. W. (2005). Diagnostic ultrasound (3rd
edition), St Louis (MO), Mosby.
[107] Bruix, J., & Sherman, M. (2005). Practice Guidelines Committee, American Associa‐
tion for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepa‐
tology, 42, 1208-1236.
[108] Cochrane, A. M., Murray-Lyon, I. M., Brinkley, D. M., & Williams, R. (1977). Quadru‐
ple chemotherapy versus radiotherapy in treatment of primary hepatocellular carci‐
noma. Cancer, 40, 609-6.
[109] Lawrence, T. S., Tesser, R. J., & ten Haken, R. K. (1990). An application of dose vol‐
ume histograms to the treatment of intrahepatic malignancies with radiation therapy.
Int J Radiat Oncol Biol Phys, 19, 1041-1047.
[110] Lawrence, T. S., Ten Haken, R. K., Kessler, M. L., et al. (1992). The use of 3-D dose
volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys, 23, 781-788.
[111] Robertson, J. M., Mc Ginn, C. J., Walker, S., et al. (1997). A phase I trial of hepatic ar‐
terial bromodeoxyuridine and conformal radiation therapy for patients with primary
hepatobiliary cancers or colorectal liver metastases. Int J Radiat Oncol Biol Phys, 39,
1087-1092.
[112] Seong, J., Keum, K. C., Han, K. H., et al. (1999). Combined transcatheter arterial che‐
moembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int
J Radiat Oncol Biol Phys, 43, 393-397.
[113] Shim, S. J., Seong, J., Han, K. H., et al. (2005). Local radiotherapy as a complement to
incomplete transcatheter arterial chemoembolization in locally advanced hepatocel‐
lular carcinoma. Liver Int, 25, 1189-1196.
[114] Park, W., Lim, D. H., Paik, S. W., et al. (2005). Local radiotherapy for patients with
unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys , 61, 1143-1150.
Hepatic Surgery454
[115] Park, JW. (2004). Korean Liver Cancer Study Group and National Cancer Center.
Practice guideline for diagnosis and treatment of hepato- cellular carcinoma. Korean J
Hepatol, 10, 88-98.
[116] Von Schweinitz, D. (2004). Treatment of liver tumors in children. In: Clavian PA, Fong
Y, Lyerly H, et al. editors. Liver tumors: current and emerging therapies, Boston, Jones and
Bartlett.
[117] Mazzaferro, V., Regalia, E., Doci, R., et al. (1996). Liver transplantation for the treat‐
ment of small hepatocellular carcinoma in patients with cirrhosis. New Engl J Med,
334, 693-9.
[118] Yao, F. Y., Ferrell, L., Bass, N. M., et al. (2001). Liver transplantation for hepatocellu‐
lar carcinoma: expansion of the tumor size limits does not adversely impact survival.
Hepatology, 33, 1394-403.
[119] Roayaie, S., Frischer, J. S., Emre, S. H., et al. (2002). Long-term results with multimo‐
dal adjuvant therapy and liver transplantation for the treatment of hepatocellular
carcinoma larger than 5 centimetres. Ann Surg, 235, 533-9.
[120] Terracciano, L., & Tornillo, L. (2003). Cytogenetic alteration in liver cell tumors as de‐
tected by comparative genomic hybridization. Pathologica, 95, 71-82.
[121] Llovet, J. M., Ricci, S., Mazzaferro, V., et al. (2008). Sorafenib in advanced hepatocel‐
lular carcinoma. New Engl J Med, 359, 420-2.
[122] Srinivasan, P., Mc Call, J., Pritchard, J., et al. (2002). Orthotopic liver transplantation
for unresectable hepatoblastoma. Transplantation, 74, 652-5.
[123] Tagge, E. P., Tagge, D. U., Reyes, J., et al. (1992). Resection, including transplan- ta‐
tion, for hepatoblastoma and hepatocellular carcinoma: impact on survival. J Pediatr
Surg, 27, 292-6, discussion 297.
[124] Freeman, R. B., Jr., & Edwards, E. B. (2000). Liver transplant waiting time does not
correlate with waiting list mortality: implications for liver allocation policy. Liver
Transplant, 6, 543-52.
[125] Organ Procurement and Transplantation Network-HRSA. (1998). Final rule with
comment period. Fed Regist, 63, 16296-338.
[126] Tiao, G. M., Alonso, M. H., & Ryckman, F. C. (2006). Pediatric liver transplantation.
Seminars in pediatric surgery, 15(3), 218-27.
[127] Schiff, E. R., Maddrey, W. C., & Sorrel, M. F. (2011). Schiff’s Disease of the Liver (11th
ed.), Wiley-Blackwell.
[128] Ehren, H., Mahour, G. H., & Isaacs, H., Jr. (1983). Benign liver tumors in infancy and
childhood. Report of 48 cases. Am J Surg, 145, 325-9.
[129] Kochin, M. D., Tamir, A., Miloh, M. D., Ronen Arnon, M. D., Kishore, R., Iyer, M. D.,
Frederick, J., Suchy, M. D., Nanda Kerkar, M., Zenge, J. P., Fenton, L., Lovell, M. A.,
Liver Tumors in Infancy
http://dx.doi.org/10.5772/51764
455
Grover, T. R., et al. (2002). Case report: infantile hemangioendothelioma. Curr Opin
Pediatr, 14, 99-102.
[130] Reymond, D., Plaschkes, J., Luthy, A. R., et al. (1995). Focal nodular hyperplasia of
the liver in children: review of follow-up and outcome. J Pediatr Surg, 30, 1590-3.
[131] Bakshi, P., Srinivasan, R., Rao, K. L., et al. (2006). Fine needle aspiration biopsy in pe‐
diatric space- occupying lesions of liver: a retrospective study evaluating its role and
diagnostic efficacy. J Pediatr Surg, 41, 1903-8.
[132] Schwartz, M. E., Konstadoulakis, M. M., Roayaie, S., et al. (2008). The Mount Sinai
experience with orthotopic liver transplantation for benign tumors: brief report and
literature review: case reports. Transplant Proc, 40, 1759-62.
[133] Finegold, M. J., Egler, R. A., Goss, J. A., et al. (2008). Liver tumors: pediatric popula‐
tion. Liver Transpl, 14, 1545-56.
[134] Zenge, J. P., Fenton, L., Lovell, M. A., & Grover, T. R. (2002). Case report: infantile
hemangioendothelioma. Curr Opin Pediatr, 14, 99-102.
[135] Mortelé, K. J., Vanzieleghem, B., Mortelé, B., Benoit, Y., & Ros, P. R. (2002). Solitary
hepatic infantile hemangioendothelioma: dynamic gadolinium-enhanced MR imag‐
ing findings. Eur Radiol, 12, 862-865.
[136] Ingram, J. D., Yerushalmi, B., Connell, J., Karrer, F. M., Tyson, R. W., & Sokol, R. J.
(2000). Hepatoblastoma in a neonate: a hypervascular presentation mimicking he‐
mangioendothelioma. Pediatr Radiol, 30, 794-797.
[137] Roos, J. E., Pfiffner, R., Stallmach, T., Stuckmann, G., Marincek, B., & Willi, U. (2003).
Infantile hemangioendothelioma. Radiographics฀: a review publication of the Radiologi‐
cal Society of North America, 23(6), 1649-55.
[138] Stringer, M. D., & Alizai, N. K. (2005). Mesenchymal hamartoma of the liver: a sys‐
tematic review. J Pediatr Surg, 40, 1681-90.
[139] Horton, K. M., Bluemke, D. A., Ralph, H., Soyer, P., & Fishman, E. K. (1999). CT and
MR Imaging of Benign Hepatic, 431-451.
[140] Zafrani, E. S. (1989). Update on vascular tumours of the liver. J Hepatology, 8(1),
125-30.
[141] Linderkamp, O., Hopner, F., Klose, H., et al. (1976). Solitary hepatic hemangioma in a
newborn infant complicated by cardiac failure, consumption coagulopathy, microan‐
giopathic hemolytic anemia, and obstructive jaundice. Case report and review of the
literature. Eur J Pediatr, 125(1), 239.
[142] Hobbs, K. E. (1990). Hepatic hemangiomas. World J Surg, 14(4), 468-71.
[143] DeLorimier, A. A., Simpson, E. B., Baum, R. S., et al. (1967). Hepatic-artery ligation
for hepatic hemangiomatosis. N Engl J Med, 277(7), 333-7.
Hepatic Surgery456
[144] Warmann, S., Bertram, H., Kardorff, R., et al. (2003). Interventional treat- ment of in‐
fantile hepatic hemangioendothelioma. J Pediatr Surg, 38(8), 1177-81.
[145] Walsh, R., Harrington, J., Beneck, D., et al. (2004). Congenital infantile hepatic he‐
mangioendothelioma type II treated with orthotopic liver transplantation. J Pediatr
Hematol Oncol, 26(2), 121-3.
[146] Lack, E. E., & Ornvold, K. (1986). Focal nodular hyperplasia and hepatic adenoma: a
review of eight cases in the pediatric age group. J Surg Oncol, 33, 129-35.
[147] Farruggia, P., Alaggio, R., Cardella, F., Tropia, S., Trizzino, A., Ferrara, F., & D’Ange‐
lo, P. (2010). Focal nodular hyperplasia of the liver: an unusual association with dia‐
betes mellitus in a child and review of literature. Italian journal of pediatrics, 36, 41,
doi: 10.1186/1824-7288-36-41.
[148] Luciani, A., Kobeiter, H., Maison, P., Cherqui, D., Zafrani, E. S., Dhumeaux, D., &
Mathieu, D. (2002). Focal nodular hyperplasia of the liver in men: is presentation the
same in men and women? Gut, 50, 877-80.
[149] Rebouissou, S., Bioulac-Sage, P., & Zucman-Rossi, J. (2008). Molecular pathogenesis
of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol, 48, 163-170.
[150] Raidl, M., Pirker, C., Schulte-Hermann, R., Aubele, M., Kandioler-Eckersberger, D.,
Wrba, F., Micksche, M., Berger, W., & Grasl-Kraupp, B. (2004). Multiple chromoso‐
mal abnormalities in human liver (pre)neoplasia. J Hepatol, 40, 660-668.
[151] Vernier-Massouille, G., Cosnes, J., Lemann, M., Marteau, P., Reinisch, W., Laharie,
D., & Cadiot, G. (2007). Nodular regenerative hyperplasia in patients with inflamma‐
tory bowel disease treated with azathioprine. Gut, 56(10), 1404-9.
[152] Stromeyer, F. W., & Ishak, K. G. (1981). Nodular transformation (nodular ‘‘regenera‐
tive’’ hyperplasia) of the liver.A clinicopathologic study of 30 cases. Hum Pathol, 12,
60-71.
[153] Wanless, I. R., Godwin, T. A., Allen, F., et al. (1980). Nodular regenerative hyperpla‐
sia of the liver in hematologic disorders: a possible response to obliterative portal ve‐
nopathy. A morphometric study of nine cases with an hypothesis on the
pathogenesis. Medicine, 59, 367-79.
[154] Naber, A. H., Van Haelst, U., & Yap, S. H. (1991). Nodular regenerative hyperplasia
of the liver: an important cause of portal hypertension in non-cirrhotic patients. J
Hepatol, 12, 94-9.
[155] Reshamwala, P. A., Kleiner, D. E., & Heller, T. (2006). Nodular regenerative hyper‐
plasia: not all nodules are created equal. Hepatology, 44, 7-14.
[156] Stocker, J. T., & Ishak, K. G. (1983). Mesenchymal hamartoma of the liver: Report of
30 cases and review of the literature. Pediatr Pathol, 1, 245-67.
[157] Gupta, R., Parelkar, S. V., & Sanghvi, B. (2009). Mesenchymal hamartoma of the liver.
Indian J Med Paediatr Oncol, 30, 141-143, doi:.
Liver Tumors in Infancy
http://dx.doi.org/10.5772/51764
457
[158] Kirks, D. R., & Griscom, N. T. (1990). Practical pediatric imaging. Lippincott Williams
and Wilkins, 3rd ed, Boston, Little, Brown, Diagnostic radiology of infants and children,
808-815.
[159] Ito, H., Kishikawa, T., Toda, T., Arai, M., & Muro, H. (1984). Hepatic mesenchymal
hamartoma of an infant. J Pediatr Surg, 19, 315-7.
[160] Bisogno, G., Pilz, T., Perilongo, G., et al. (2002). Undifferentiated sarcoma of the liver
in childhood: A curable disease. Cancer, 94, 252-257.
[161] Lack, E. E., Schloo, B. L., Azumi, Net, et al. (1991). Undifferentiated (embryonal) sar‐
coma of the liver.Clinical and pathological study of 16 cases with emphasis on immu‐
nohistochemical features. Am J Surg Pathol, 15, 1-16.
[162] Chuang, W.-yu., Lin, J.-nan., Hung, I.-jih., & Hsueh, C. (2001). Undifferentiated Sarco‐
ma of the Liver, 399-404.
[163] Foster, J. H., & Berman, M. M. (1977). Solid Liver Tumors, Philadelphia, W. B. Saun‐
ders, 198-202.
[164] Donovan, E. J., & Santulli, T. V. (1946). Resection of the left lobe of the liver for mes‐
enchymoma- Report of case. Ann Surg, 124, 90-3.
[165] Willeford, G., & Stembridge, V. A. (1950). Primary sarcoma of liver- Report of a case.
Am J Dis Child, 80, 404-7.
[166] Dintzman, M., Reiss, R., & Haimoff, H. (1966). Right hepatectomy. Isr J Med Sci, 2,
743-9.
[167] Noguchi, K., Yokoo, H., Nakanishi, K., Kakisaka, T., Tsuruga, Y., Kamachi, H., Mat‐
sushita, M., et al. (2012). A long-term survival case of adult undifferentiated embry‐
onal sarcoma of liver. World journal of surgical oncology, 10(1), 65.
[168] Walker, N. I., Horn, M. J., Strong, R. W., Lynch, S. V., Cohen, J., Ong, T. H., & Harris,
O. D. (1992). Undifferentiated (embryonal) sarcoma of the liver: Pathologic findings
and long-term survival after complete surgical resection. Cancer, 69(1), 52-59.
[169] Aoyama, C., Hachitanda, Y., Sato, J. K., Said, J. W., & Shimada, H. (1991). Undifferen‐
tiated (embryonal) sarcoma of the liver. A tumor of uncertain histogenesis showing
divergent differentiation. Am J Surg Pathol, 15, 615-24.
[170] Chou, P., Mangkornkanok, M., & Gonzalez-Crussi, F. (1990). Undifferentiated (em‐
bryonal) sarcoma of the liver: ultrastructure, immunohistochemistry, and DNA ploi‐
dy analysis of two cases. Pediatr Pathol, 10, 549-62.
[171] Keating, S., & Taylor, G. P. (1985). Undifferentiated (embryonal) sarcoma of the liver:
ultrastructural and immunohistochemical similarities with malignant fibrous histio‐
cytoma. Hum Pathol, 16, 693-9.
Hepatic Surgery458
[172] Buetow, P. C., Buck, J. L., Pantongrag-Brown, L., Marshall, W. H., Ros, P. R., Levine,
M. S., & Goodman, Z. D. (1997). Undifferentiated embryonal sarcoma of the liver:
pathological basis of imaging findings in 28 cases. Radiology, 203, 779-783.
[173] Urban, C. E., Mache, C. J., Schwinger, W., Pakisch, B., Ranner, G., Riccabona, M.,
Schimpl, G., Brandesky, G., Messner, H., Pobegen, W., Becker, H., & Grienberger, H.
(1993). Undifferentiated (embryonal) sarcoma of the liver in childhood. Successful
combined-modality therapy in four patients. Cancer, 72, 2511-6.
[174] Newman, K. D., Schisgall, R., Reaman, G., & Guzzetta, P. C. (1989). Malignant mes‐
enchymoma of the liver in cildren. J Pediatr Surg, 24, 781-3.
[175] Kirks, D. R., & Griscom, N. T. (1990). Practical pediatric imaging. editors. Lippincott
Williams and Wilkins, 3rd ed., Boston, Little, Brown, Diagnostic radiology of infants
and children, 808-815.
Liver Tumors in Infancy
http://dx.doi.org/10.5772/51764
459

